Exelixis Inc at Piper Jaffray Healthcare Conference Transcript
Good morning, everyone. My name is Ted Tenthoff. I'm a senior biotech analyst at Piper Jaffray. And before I begin, I'm required to point out certain disclosures regarding the relationship between Piper and our next presenting company, Exelixis, which are listed both at the back of the room and also at the registration desk. CABOMETYX is currently approved in first- and second-line kidney cancer as well as second-line liver cancer. Exelixis is conducting multiple Phase III trials in combination with checkpoint inhibitors to become competitive in the frontline setting.
Here with us today is Chris Senner, CFO; and Andrew Peters, who's the VP of Strategy. And I believe to start us off, Chris has some introductory remarks to make.
Yes. Thanks, Ted. So before I get started, I'd just like to point everybody to -- refer everybody to our SEC filings for risks associated with our business. Also
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
